Whether immunomodulators or biological treatments (anti-TNFα therapy) increase the risk of post-operative complications in Crohn’s disease patients is still a matter of debate [4,5,9,10,22,23,24,25,26,27,28]. This evidence concerns the gene TNF and Crohn disease.